Arno Therapeutics, Inc 5
5 · Arno Therapeutics, Inc · Filed Feb 17, 2015
Insider Transaction Report
Form 5
Ruchefsky Steven B
Director
Transactions
- Disposition to Issuer
2013 Series E Warrants (right to buy)
2014-10-28−687,500→ 0 total(indirect: By LLC)Exercise: $2.40From: 2013-10-29Exp: 2014-12-31→ Common Stock (687,500 underlying) - Disposition to Issuer
2012 Series B Warrants (right to buy)
2014-10-28−520,833→ 0 total(indirect: By LLC)Exercise: $2.40From: 2013-10-29Exp: 2014-10-31→ Common Stock (520,833 underlying) - Award
2012 Series B Warrants (right to buy)
2014-10-28+520,833→ 520,833 total(indirect: By LLC)Exercise: $2.40From: 2013-10-29Exp: 2015-01-31→ Common Stock (520,833 underlying) - Award
2013 Series E Warrants (right to buy)
2014-10-28+687,500→ 687,500 total(indirect: By LLC)Exercise: $2.40From: 2013-10-29Exp: 2015-01-31→ Common Stock (687,500 underlying)
Holdings
- 1,596,272(indirect: By LLC)
Common Stock
Footnotes (2)
- [F1]The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
- [F2]The reported transaction resulted from the Issuer's unilateral extension of the expiration date of the outstanding warrant from 10/31/14 to 1/31/15. Such extension resulted in the deemed cancellation of the "originally" issued old warrant and the issuance of a replacement warrant. The Series E warrant was originally granted on 10/29/13.